EBS Emergent BioSolutions Inc

  1. Stocks
  2. Healthcare
  3. NYSE: EBS

Price (delayed)

$13.97

Market cap

$732.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$10.94

Enterprise value

$1.56B

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated ...

Highlights
EBS's gross profit has soared by 70% year-on-year and by 42% since the previous quarter
EBS's gross margin is up by 41% YoY and by 26% QoQ
EBS's equity is down by 45% year-on-year but it is up by 2.2% since the previous quarter
The net income has contracted by 42% YoY but it has grown by 26% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.emergentbiosolutions.com
Peers: MRK SIGA CMRX XOMA

Key stats

What are the main financial stats of EBS
Market
Shares outstanding
52.4M
Market cap
$732.05M
Enterprise value
$1.56B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.1
Price to sales (P/S)
0.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.32
Earnings
Revenue
$1.19B
EBIT
-$464.2M
EBITDA
-$345.8M
Free cash flow
-$132.2M
Per share
EPS
-$10.94
Free cash flow per share
-$2.53
Book value per share
$12.72
Revenue per share
$22.71
TBVPS
$24.01
Balance sheet
Total assets
$1.8B
Total liabilities
$1.14B
Debt
$905.9M
Equity
$663.9M
Working capital
$52.2M
Liquidity
Debt to equity
1.36
Current ratio
1.08
Quick ratio
0.5
Net debt/EBITDA
-2.39
Margins
EBITDA margin
-29.2%
Gross margin
41.2%
Net margin
-47.7%
Operating margin
-45.5%
Efficiency
Return on assets
-29.4%
Return on equity
-76.2%
Return on invested capital
-32.5%
Return on capital employed
-39.6%
Return on sales
-39.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EBS stock price

How has the Emergent BioSolutions stock price performed over time
Intraday
1.23%
1 week
24.73%
1 month
112.96%
1 year
95.11%
YTD
482.08%
QTD
104.84%

Financial performance

How have Emergent BioSolutions's revenue and profit performed over time
Revenue
$1.19B
Gross profit
$488.3M
Operating income
-$539M
Net income
-$565.2M
Gross margin
41.2%
Net margin
-47.7%
EBS's gross profit has soared by 70% year-on-year and by 42% since the previous quarter
EBS's operating income has plunged by 68% YoY but it is up by 26% from the previous quarter
The net income has contracted by 42% YoY but it has grown by 26% from the previous quarter
EBS's gross margin is up by 41% YoY and by 26% QoQ

Growth

What is Emergent BioSolutions's growth rate over time

Valuation

What is Emergent BioSolutions stock price valuation
EBS P/E details
P/E
N/A
P/B
1.1
P/S
0.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.32
EBS's EPS is down by 38% year-on-year but it is up by 26% since the previous quarter
EBS's equity is down by 45% year-on-year but it is up by 2.2% since the previous quarter
The price to book (P/B) is 36% lower than the 5-year quarterly average of 1.7
The P/S is 62% below the 5-year quarterly average of 1.6
The company's revenue rose by 21% YoY and by 13% QoQ

Efficiency

How efficient is Emergent BioSolutions business performance
EBS's return on equity has dropped by 166% year-on-year but it is up by 12% since the previous quarter
The company's return on assets has shrunk by 118% YoY but it rose by 15% QoQ
EBS's ROIC has shrunk by 107% YoY but it is up by 22% QoQ
EBS's ROS is up by 36% since the previous quarter but it is down by 18% year-on-year

Dividends

What is EBS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EBS.

Financial health

How did Emergent BioSolutions financials performed over time
The total assets is 58% more than the total liabilities
The total assets has contracted by 39% YoY
The company's total liabilities fell by 35% YoY and by 2.9% QoQ
Emergent BioSolutions's debt is 36% higher than its equity
EBS's equity is down by 45% year-on-year but it is up by 2.2% since the previous quarter
Emergent BioSolutions's debt has decreased by 35% YoY but it has increased by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.